775 — CK Life Sciences Intl (Holdings) Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$3.32bn
- HK$8.57bn
- HK$5.32bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 217 | 119 | 238 | 205 | 68.6 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 66.7 | 86.9 | 98.5 | 97.2 | 209 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -109 | 105 | -160 | -169 | 2.84 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 379 | 531 | 424 | 364 | 514 |
Capital Expenditures | -198 | -380 | -217 | -217 | -292 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -56.1 | -77.5 | -40.6 | 195 | 224 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -254 | -457 | -258 | -22.1 | -68 |
Financing Cash Flow Items | -324 | -134 | -98.1 | -163 | -321 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -192 | 169 | -220 | -515 | -478 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -76.9 | 262 | -68.2 | -199 | -27.6 |